Fidaxomicin - the new drug for Clostridium difficile infection.

Simple item page
dc.contributor.authorVaishnavi, Chetana
dc.date.accessioned2016-01-07T07:09:28Z
dc.date.available2016-01-07T07:09:28Z
dc.date.issued2015-04
dc.description.abstractClostridium difficile is one of the many aetiological agents of antibiotic associated diarrhoea and is implicated in 15-25 per cent of the cases. The organism is also involved in the exacearbation of inflammatory bowel disease and extracolonic manifestations. Due to increase in the incidence of C. difficile infection (CDI), emergence of hypervirulent strains, and increased frequency of recurrence, the clinical management of the disease has become important. The management of CDI is based on disease severity, and current antibiotic treatment options are limited to vancomycin or metronidazole in the developing countries. this review article briefly describes important aspects of CDI, and the new drug, fidaxomicin, for its treatment. Fidaxomicin is particularly active against C.difficile and acts by inhibition of RNA synthesis. Clinical trials done to compare the efficacy and safety of fidaxomicin with that of vancomycin in treating CDI concluded that fidaxomicin was non-inferior to vancomycin for treatment of CDI and that there was a significant reduction in recurrences. The bactericidal properties of fidaxomicin make it an ideal alternative for CDI treatment. However, fidaxomicin use should be considered taking into account the potential benefits of the drug, along with the medical requirements of the patient, the risks of treatment and the high cost of fidaxomicin compared to other treatment regimens.en_US
dc.identifier.citationVaishnavi Chetana. Fidaxomicin - the new drug for Clostridium difficile infection. Indian Journal of Medical Research. 2015 Apr; 141(4): 398-407.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/170122
dc.language.isoenen_US
dc.source.urihttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4510719/en_US
dc.subjectclinical trialsen_US
dc.subjectClostridium difficileen_US
dc.subjectcosten_US
dc.subjectdiarrhoeaen_US
dc.subjectfidaxomicinen_US
dc.subjecthypervirulent strainen_US
dc.subjectrecurrencesen_US
dc.subjectvancomycinen_US
dc.titleFidaxomicin - the new drug for Clostridium difficile infection.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijmr2015v141n4p398.pdf
Size:
392.84 KB
Format:
Adobe Portable Document Format
Description:
Review article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Medical Research